Factors influencing serum CA125II levels in healthy postmenopausal women

Donna P Ankerst, U. Menon, M. McIntosh, H. L. Symecko, S. J. Skates, I. J. Jacobs

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Our objective was to identify factors that correlate with CA125 concentrations in healthy postmenopausal women and to introduce recommendations for reporting and interpreting individual CA125 assay results. We analyzed repeated serum CA125 levels, as measured by the CA125II assay, in 18,748 postmenopausal women who participated in the St. Bartholomew's/Royal London Hospital Ovarian Cancer screening trial from 1986 to 1994 and were not diagnosed with ovarian cancer during the 12-year follow-up period. We found that race is a substantial predictor of normal levels of CA125, with average CA125II concentration from African (median, 9.0; 95% range, 4.0-26.0 units/ml) and Asian women (median, 13.0; range, 5.9-33.3 units/ml) lower than that in Caucasian women (median, 14.2; range, 6.0-41.0 units/ml; P < 0.001). Women with a hysterectomy have lower CA125II values (median, 13.6; range 5.5-39.0 units/ml; P < 0.001), and women with a prior cancer diagnosis other than ovarian cancer have higher levels of CA125 II (median, 16.0; range, 6.0-49.0 units/ml; P < 0.003). Regular smoking and caffeine consumption decrease CA125 levels (P < 0.001). A woman's age, age at menarche, age at menopause, and history of a previous ovarian cyst (P < 0.05) are also predictive of baseline CA125 levels. Parity, history of hormone replacement therapy or unilateral oopherectomy, and previous use of oral contraceptives or talcum powder are not significant predictors of CA125 concentrations (P > 0.05). We concluded that clinically significant differences in individual patient characteristics need to be reflected in the screening algorithms that use CA125II so that designed performance characteristics (sensitivity and specificity) are maintained in practice.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume10
Issue number5
StatePublished - 2001
Externally publishedYes

Fingerprint

Serum
Ovarian Neoplasms
Early Detection of Cancer
Individuality
Sensitivity and Specificity

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Ankerst, D. P., Menon, U., McIntosh, M., Symecko, H. L., Skates, S. J., & Jacobs, I. J. (2001). Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiology Biomarkers and Prevention, 10(5), 489-493.

Factors influencing serum CA125II levels in healthy postmenopausal women. / Ankerst, Donna P; Menon, U.; McIntosh, M.; Symecko, H. L.; Skates, S. J.; Jacobs, I. J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 10, No. 5, 2001, p. 489-493.

Research output: Contribution to journalArticle

Ankerst, DP, Menon, U, McIntosh, M, Symecko, HL, Skates, SJ & Jacobs, IJ 2001, 'Factors influencing serum CA125II levels in healthy postmenopausal women', Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 5, pp. 489-493.
Ankerst DP, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiology Biomarkers and Prevention. 2001;10(5):489-493.
Ankerst, Donna P ; Menon, U. ; McIntosh, M. ; Symecko, H. L. ; Skates, S. J. ; Jacobs, I. J. / Factors influencing serum CA125II levels in healthy postmenopausal women. In: Cancer Epidemiology Biomarkers and Prevention. 2001 ; Vol. 10, No. 5. pp. 489-493.
@article{9cb957fee2eb4bb29c956a82b23d286b,
title = "Factors influencing serum CA125II levels in healthy postmenopausal women",
abstract = "Our objective was to identify factors that correlate with CA125 concentrations in healthy postmenopausal women and to introduce recommendations for reporting and interpreting individual CA125 assay results. We analyzed repeated serum CA125 levels, as measured by the CA125II assay, in 18,748 postmenopausal women who participated in the St. Bartholomew's/Royal London Hospital Ovarian Cancer screening trial from 1986 to 1994 and were not diagnosed with ovarian cancer during the 12-year follow-up period. We found that race is a substantial predictor of normal levels of CA125, with average CA125II concentration from African (median, 9.0; 95{\%} range, 4.0-26.0 units/ml) and Asian women (median, 13.0; range, 5.9-33.3 units/ml) lower than that in Caucasian women (median, 14.2; range, 6.0-41.0 units/ml; P < 0.001). Women with a hysterectomy have lower CA125II values (median, 13.6; range 5.5-39.0 units/ml; P < 0.001), and women with a prior cancer diagnosis other than ovarian cancer have higher levels of CA125 II (median, 16.0; range, 6.0-49.0 units/ml; P < 0.003). Regular smoking and caffeine consumption decrease CA125 levels (P < 0.001). A woman's age, age at menarche, age at menopause, and history of a previous ovarian cyst (P < 0.05) are also predictive of baseline CA125 levels. Parity, history of hormone replacement therapy or unilateral oopherectomy, and previous use of oral contraceptives or talcum powder are not significant predictors of CA125 concentrations (P > 0.05). We concluded that clinically significant differences in individual patient characteristics need to be reflected in the screening algorithms that use CA125II so that designed performance characteristics (sensitivity and specificity) are maintained in practice.",
author = "Ankerst, {Donna P} and U. Menon and M. McIntosh and Symecko, {H. L.} and Skates, {S. J.} and Jacobs, {I. J.}",
year = "2001",
language = "English (US)",
volume = "10",
pages = "489--493",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Factors influencing serum CA125II levels in healthy postmenopausal women

AU - Ankerst, Donna P

AU - Menon, U.

AU - McIntosh, M.

AU - Symecko, H. L.

AU - Skates, S. J.

AU - Jacobs, I. J.

PY - 2001

Y1 - 2001

N2 - Our objective was to identify factors that correlate with CA125 concentrations in healthy postmenopausal women and to introduce recommendations for reporting and interpreting individual CA125 assay results. We analyzed repeated serum CA125 levels, as measured by the CA125II assay, in 18,748 postmenopausal women who participated in the St. Bartholomew's/Royal London Hospital Ovarian Cancer screening trial from 1986 to 1994 and were not diagnosed with ovarian cancer during the 12-year follow-up period. We found that race is a substantial predictor of normal levels of CA125, with average CA125II concentration from African (median, 9.0; 95% range, 4.0-26.0 units/ml) and Asian women (median, 13.0; range, 5.9-33.3 units/ml) lower than that in Caucasian women (median, 14.2; range, 6.0-41.0 units/ml; P < 0.001). Women with a hysterectomy have lower CA125II values (median, 13.6; range 5.5-39.0 units/ml; P < 0.001), and women with a prior cancer diagnosis other than ovarian cancer have higher levels of CA125 II (median, 16.0; range, 6.0-49.0 units/ml; P < 0.003). Regular smoking and caffeine consumption decrease CA125 levels (P < 0.001). A woman's age, age at menarche, age at menopause, and history of a previous ovarian cyst (P < 0.05) are also predictive of baseline CA125 levels. Parity, history of hormone replacement therapy or unilateral oopherectomy, and previous use of oral contraceptives or talcum powder are not significant predictors of CA125 concentrations (P > 0.05). We concluded that clinically significant differences in individual patient characteristics need to be reflected in the screening algorithms that use CA125II so that designed performance characteristics (sensitivity and specificity) are maintained in practice.

AB - Our objective was to identify factors that correlate with CA125 concentrations in healthy postmenopausal women and to introduce recommendations for reporting and interpreting individual CA125 assay results. We analyzed repeated serum CA125 levels, as measured by the CA125II assay, in 18,748 postmenopausal women who participated in the St. Bartholomew's/Royal London Hospital Ovarian Cancer screening trial from 1986 to 1994 and were not diagnosed with ovarian cancer during the 12-year follow-up period. We found that race is a substantial predictor of normal levels of CA125, with average CA125II concentration from African (median, 9.0; 95% range, 4.0-26.0 units/ml) and Asian women (median, 13.0; range, 5.9-33.3 units/ml) lower than that in Caucasian women (median, 14.2; range, 6.0-41.0 units/ml; P < 0.001). Women with a hysterectomy have lower CA125II values (median, 13.6; range 5.5-39.0 units/ml; P < 0.001), and women with a prior cancer diagnosis other than ovarian cancer have higher levels of CA125 II (median, 16.0; range, 6.0-49.0 units/ml; P < 0.003). Regular smoking and caffeine consumption decrease CA125 levels (P < 0.001). A woman's age, age at menarche, age at menopause, and history of a previous ovarian cyst (P < 0.05) are also predictive of baseline CA125 levels. Parity, history of hormone replacement therapy or unilateral oopherectomy, and previous use of oral contraceptives or talcum powder are not significant predictors of CA125 concentrations (P > 0.05). We concluded that clinically significant differences in individual patient characteristics need to be reflected in the screening algorithms that use CA125II so that designed performance characteristics (sensitivity and specificity) are maintained in practice.

UR - http://www.scopus.com/inward/record.url?scp=0034921718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034921718&partnerID=8YFLogxK

M3 - Article

C2 - 11352859

AN - SCOPUS:0034921718

VL - 10

SP - 489

EP - 493

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -